Media
Home
Media
- Press
Minoryx Phase 2/3 ‘ADVANCE’ study results to be presented at the 2021 American Neurological Association (AAN) Annual MeetingAdditional clinical data will show benefits of leriglitazone in adrenomyeloneuropathy (...12/04/2021
Minoryx presents topline results from Phase 2/3 “ADVANCE” study demonstrating significant clinical benefit of leriglitazone in adrenomyeloneuropathy (AMN)Largest prospective efficacy study conducted in the orphan disease AMN ...26/01/2021
Minoryx’s clinical candidate leriglitazone shows clinical benefit in a proof of concept Phase 2 study in Friedreich´s ataxiaStudy demonstrates leriglitazone improves relevant disease biomarkers and ataxia resulting ...15/12/2020Read more
- Events
Events in 2021
Events in 2020Events in 201911 Nov 2019 - 13 Nov 2019World Orphan Drug CongressBARCELONA11 Nov 2019 - 13 Nov 2019BIO-Europe 2019HAMBURG
